Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: September 27, 2022

Details for Patent: 8,536,167

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,536,167 protect, and when does it expire?

Patent 8,536,167 protects XTORO and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: 8,536,167
Title:Methods for treating ophthalmic, otic, or nasal infections
Abstract: The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.
Inventor(s): Stroman; David W. (Irving, TX), Chowhan; Masood A. (Arlington, TX), Appell; Kenneth C. (Burleson, TX)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:12/829,973
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,536,167

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing TREATMENT OF ACUTE OTITIS EXTERNA See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,536,167

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077372 See Plans and Pricing
Australia 2010266120 See Plans and Pricing
Brazil PI1016257 See Plans and Pricing
Canada 2765852 See Plans and Pricing
Chile 2011003327 See Plans and Pricing
China 102470139 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.